Podcasts about Recurrence

Join Dr. Kristi Funk, M.D., FACS, as she discusses the benefits of exercise in reducing cancer risk and improving overall health. Learn about a study showing how exercise reduces cancer recurrence and mortality rates. Discover how exercise and healthy eating improve chemotherapy outcomes and explore key lifestyle changes to reduce breast cancer risk. Find out about the resources and support available at the Pink Lotus Breast Center, including the Power Up social community, Breast Buddies program, monthly cooking show, and upcoming summit events. #CancerPrevention #ExerciseForHealth #BreastCancerAwareness 

No doubt you've heard that certain diets may reduce your recurrence risk, but what about certain nutrients? Currently science doesn't back up the idea that specific nutrient recommendations are the ultimate way to minimize your recurrence risk, however, there is nuance to that. In today's episode I dig into what you need to know about nutrient-dense diets in order to make the best food choices for you!________________________________________Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here!Follow me on Instagram @hormone.breastcancer.dietitian

Regular, supervised exercise helped people who'd been treated for colorectal cancer avoid recurrence of the disease, a new study shows, adding to the burgeoning body of evidence demonstrating the clear health benefits of exercise in many settings, including avoiding cancer … Supervised exercise helped reduce recurrence of colorectal cancer, Elizabeth Tracey reports Read More »

Join Dr. Kristi Funk, M.D., FACS, as she explains how obesity increases cancer risk by focusing on inflammation, estrogen production, and leptin levels. Discover the benefits of exercise in reducing cancer risk, improving overall health, and enhancing chemotherapy outcomes. Learn about key lifestyle changes to lower breast cancer risk and explore the resources and support available at the Pink Lotus Breast Center. #CancerPrevention #HealthyLiving #BreastCancerAwareness

On today's episode, the guys discuss a study surrounding exercise and cancer recurrence. We want to hear from you again! Send us an email to RickandDannyShow@gmail.comOr, message us on social media:Facebook: The Rick & Danny ShowInsta: @RickAndDannyShowTwitter: @_CSNF Hosted on Acast. See acast.com/privacy for more information.

In this episode, UROONCO PCa chief editor Dr. Giancarlo Marra speaks to Prof. Derya Tilki (DE) about the 2025 updates in the EAU Prostate Cancer Guidelines, specifically regarding high risk, locally advanced disease and biochemical recurrence. This discussion includes changes such as the use of PSMA-PET-CT for staging, and updates related to lymphadenectomy. 

Join Dr. Kristi Funk as she breaks down breast cancer risk factors into "Boulders" and "Pebbles." Learn why diet, nutrition, alcohol, exercise, and obesity are major factors, and how you can reduce your risk. This insightful talk empowers you to take control of your health. #BreastCancerAwareness #HealthyLiving #CancerPrevention

218: In this episode, I'm covering one of the most requested and controversial topics in women's health—whether breast cancer survivors can safely use hormone replacement therapy (HRT). To help answer this complex question, I'm joined by Dr. Corinne Menn, a board-certified OB-GYN, Menopause Society certified practitioner, and Fellow of the American College of Obstetrics and Gynecology. Dr. Menn brings a powerful blend of clinical expertise and lived experience. She's a 23-year breast cancer survivor, BRCA gene carrier, and went through premature menopause herself. We cover what the research really says about HRT after breast cancer, risks versus benefits, the reality of estrogen deprivation, and why “it depends” is the only honest answer. Topics Discussed: → Can breast cancer survivors safely use HRT? → Is hormone therapy after breast cancer risky? → What are the benefits of estrogen for cancer survivors? → Does HRT increase breast cancer recurrence? → Are there safe hormone options for BRCA carriers? Sponsored By: → Timeline | Head to timeline.com/DRTYNA and get 20% off with code DRTYNA  → Nutrisense | Head over to nutrisense.io/drtyna to get 30% off your Nutrisense plan. Code TYNA at checkout → LVLUP | Head over to LVLUPHealth.com and use code DRTYNA at checkout to get 20% off your order sitewide.  → Manukora | Head to manukora.com/DRTYNA to save up to 31% & $25 worth of free gifts in Starter Kit, which comes with an MGO 850+ Manuka Honey jar. → BIOptimizers | Go to bioptimizers.com/tyna and use promo code TYNA10 to order Masszymes now and get 10% off any order → Dr Tyna's Brain spark | Go to store.drtyna.com/products/brainspark and use code BRAINSPARK10 for 10%  On This Episode We Cover:  → 00:00:00 - Introduction  → 00:04:51 - Dr. Menn's cancer story → 00:07:09 - Estrogen loss effects → 00:11:45 - Surgical menopause → 00:15:05 - Estrogen and cancer risk → 00:25:32 - Pregnancy after cancer → 00:31:40 - Estrogen in midlife → 00:34:45 - HRT after breast cancer → 00:37:56 - Recurrence risk → 00:44:06 - Dangers of low estrogen → 00:50:34 - New HRT options → 00:58:05 - Sexual health & dryness → 01:04:02 - You don't need to suffer → 01:08:16 - Estrogen and surgery → 01:13:04 - Estrogen for tissue health Show Links: → Estrogen Matters (book) Further Listening:  → EP. 199 | Hot Flashes Are a Warning Sign: The Truth About Metabolic Dysfunction | Quick + Dirty → Hormones Playlist Check Out Dr. Menn: → Instagram  → Website  → More Dr. Menn Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

In this episode: Importance of recognising toxic patients and considering cellulitis and deep vein thrombosis Being wary of bilateral cellulitis and considering lipodermatosclerosis in patients with recurrent cellulitis Importance of early treatment, including compression stockings, elevation, and topical steroids Need for timely referral for symptomatic relief Host: Dr David Lim, GP and Medical Educator Expert: Dr Philip Tong, Dermatologist Total time: 19 mins Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

Welcome! and Thank you for listening. This week I discuss the evolution of the podcast, the role of AI in medical information, and the importance of personalized treatment. We talk about the implications of organ aging, the significance of nutrition and exercise in health, and presents a study linking exercise to improved cancer survival rates. Additionally, we touch on insights into training for endurance events and practical advice for implementing healthy changes in daily life. I hope this episode inspires you to keep showing up, taking care of yourself, and finding joy in the journey.   LEARN MORE If you would like help with your healthy journey check out the website at https://doctordulaney.com/membership/join-us/ Email me with questions at jami@doctordulaney.com Dietary consultations: addie@doctordulaney.com Strength training programing: natha@doctordulaney.com Cookbook: https://a.co/d/6zVUluq Ebook: https://doctordulaney.com/powerful-plates-ebook/ Water distillers: https://mypurewater.com/?sld=jdulaney Find me on Facebook, Instagram, X (Twitter): @jaimeladulaney

In this audio summary, Costel Zagan asks, in dogs diagnosed with gastric dilatation and volvulus (GDV), does gastric decompression and gastropexy reduce the risk of recurrence of dilatation compared to dogs undergoing gastric decompression alone? Read the full Knowledge Summary here. Audio Summaries are a free resource that enable vets and vet nurses to more quickly and more easily access and digest relevant and up-to-date evidence! A time-saving way to make better and faster evidence-based decisions.

Join Dr. Kristi Funk as she debunks the myth about protein intake and reveals top plant-based sources. Learn why you don't need to worry about protein deficiency and discover the power of soy, lentils, beans, and more. Transform your diet with these delicious and nutritious options! #PlantBasedProtein #HealthyEating #BreastCancerPrevention

Learn the terms healthcare teams use after cancer treatment is complete, and why they hesitate to use the word "cured."  https://bit.ly/3FfnfUxAdvances in cancer diagnosis, screening, and treatment have greatly improved the 5-year survival rates of most people with cancer over the last 30 years. Long-term survivors of cancer are more and more common, and research is increasingly directed at helping people live well after a diagnosis of cancer. But even so, many oncologists still hesitate to use the word “cure” with their patients. We talk with Dr. Jeanne Ford about the difference between the terms No Evidence of Disease (NED), remission, cure, and cancer free.In this Episode: 03:11 | Travel-Vermont and Vermont Chicken Pot Pie04:25 | The Trouble with Using the Phrase "Cancer Free"10:20 | Why We Don't Say Cancer is Cured12:00 | How Dr Ford Explains NED to Her Patients19:17 | What Does "Cure" Really Mean?29:38  | How Do Native Communities Treat the Concept of a Cancer Cure32:51 | The Role of Hope and How to Deliver Honest Information37:28 | Addressing Fear of Recurrence and Uncertainty about Future44:13 | Cancer Survivorship and Surveillance46:03 | Outro#survivor #cancersurvivor #cancerfree #remisssion #NED #cancercured #treatmentfinished #survivorship #oncologynurse #caregiver #palliativecare #everyonedies #everydayisagift #cancerjourneySupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Board-Certified cardiologist, Thomas Levy, MD, JD, is known for his work with vitamin C, hydrogen peroxide, and oral toxin detox. To learn more, we have The Roadmap to Health and Optimal Treatment of Disease virtual workshops available to you online. But after more than a year of battling a recurrence of Epstein-Barr Virus (EBV), despite […]

Beyond the Digest are bonus episodes to the DermSurgery Digest that include reviews of interesting and relevant articles from JAMA Network and JAAD. Articles featured in this episode include: ·        “Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site managed by watchful waiting: A retrospective cohort study” JAAD·        “Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma” JAMA Network·        “A multicenter validation study of Mohs micrographic surgery versus wide local excision in primary high-stage cutaneous squamous cell carcinoma” JAAD·        “Identifying the impact of minor risk factors in Brigham and Women's Hospital stage T1 cutaneous squamous cell carcinomas on risk of poor outcomes: A retrospective cohort study” JAAD·        “Prevalence of poor outcomes in cutaneous squamous cell carcinoma by AJCC and BWH tumor stages: A systematic review and meta-analysis” JAAD·        “Lymphovascular invasion is an independent predictor of metastasis and disease-specific death in cutaneous squamous cell carcinoma: A multicenter retrospective study” JAAD·        “riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma” JAAD  Beyond the Digest Contributors include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Yesul Kim, MD, Beyond the Digest Co-host; Caresse Gamret, MD; Tara Jennings, MD; Sydney Proffer, MD; Yssra Soliman, MD; Kathryn Shahwan, MD; Ami Greene, MD; and. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Assessing Recurrence Following Pulsed Field Ablation for Atrial Fibrillation   Guest: Nicholas Tan, M.D., M.S. Host: Anthony H. Kashou, M.D.   Pulsed field ablation has been rapidly adopted across the United States since FDA approval was granted 1 year ago, due to its excellent acute efficacy, favorable safety profile, and fast workflow. However, recurrences post-ablation are comparable to that of previously established modalities, making this a significant hurdle that has yet to be overcome. Changes to mapping/ablation strategies, updates to PFA parameters, autonomic modulation, and combination modality ablations (PFA/RFA) offer some avenues for improvement   Topics Discussed:  What is pulsed field ablation (PFA) and how does it differ from previously established modalities of ablation such as radiofrequency and cryoablation? What are the recurrence rates post-PFA and how do they compare with other modalities? In patients who undergo redo ablations following an index PFA procedure, what are the most common causes (i.e. reconnection of pulmonary veins versus new sites)? How do you think PFA will evolve in the coming years   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

157

As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in tumour-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Both excellent studies raise the question of newer technologies and how we apply this information to trials that already exist.Studies discussed in the episode:EMBARKSOLAR/SATURNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

Because of breast cancer, fear of cancer recurrence is a permanent part of my life. I continue taking tamoxifen to reduce my risk of the cancer coming back. In this episode I share my thoughts on the good quality of life I have while taking tamoxifen. I value my strong body and theimited side-effects I have now. I also value a life with the lowest possible risk of breast cancer recurrence. I look forward to discussing what it might mean to switch to an aromatase inhibitor, in terms of further lowering the risk of recurrence and potentially experiencing more serious side-effects, with my oncologist  On more than one occasion, the oncologist has brought up endocrine therapy and the possibility of switching from tamoxifen to an aromatase inhibitor “in the future”.  Even my breast surgeon provided a quick plug for the lower risk of recurrence associated with taking aromatase inhibitors, compared to tamoxifen, without highlighting any of the aromatase inhibitor side-effects.  Determining what might be the best endocrine therapy for me to prevent recurrence is not going to be easy.  So far, neither doctor has done a deep dive into the different side-effects among the two drugs or what a change might do to overall health and quality of life.   Thank you for listening to my story! If you'd like to be the first to receive updates and exclusive content from the upcoming Breast Cancer Life newsletter, please email me at connect@breastcancerlife.org. I'd love to have you on the list! LET'S CONNECT: connect@breastcancerlife.org  Follow us on Pinterest 

In this eye-opening video, Dr. Kristi Funk unveils the shocking truth about chicken and its connection to breast cancer. Learn how cooked meats like chicken contain harmful compounds like FIP, which fuel breast cancer growth. Discover how eliminating meat can drastically reduce these risks within just 24 hours. Don't miss this vital information for your health! #BreastCancerAwareness #HealthyEating #CancerPrevention

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

When you think about food in your breast cancer survivorship journey, what comes up for you? Panic, fear and stress, or joy, ease and peace? I want the latter of those options for you, and learning how food supports you in survivorship can help move you in that direction. Join me to hear my take on three key points in understanding post-treatment nutrition and its powerful connection to your survivorship! ____________________________Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here!Follow me on Instagram @hormone.breastcancer.dietitian

Summary In this episode of the Future of Dermatology Podcast, we share a truncated replay of Dr. Daniel Klufas's session from the SF Derm 2024 Annual Conference on the management of Hydradenitis Suppurativa (HS) with a focus on the surgical technique of deroofing. This session covers the importance of medical optimization, patient selection, and the benefits of deroofing, including low recurrence rates and high patient satisfaction. Dr. Klufas emphasizes the need for thorough preoperative planning and the role of patient expectations in surgical outcomes. Takeaways - HS was long considered a purely surgical disease. - Recent strides in medical management can delay surgical intervention. - Deroofing is a critical procedure for managing HS. - Medical optimization is essential before considering surgery. - Patients should be well-informed about their treatment options. - Deroofing can be performed on solitary or regional lesions. - Patient satisfaction rates for deroofing are high. - Recurrence rates for deroofing are generally low. - Preoperative planning is crucial for successful outcomes. - Pain management post-deroofing is often less than expected. Chapters 00:00 - Introduction to the Future of Dermatology Podcast 01:00 - Understanding Hydradenitis Suppurativa (HS) and Surgical Management 03:14 - Medical Optimization and Patient Selection for Deroofing 05:01 - Deroofing Technique and Surgical Pearls 08:15 - Patient Satisfaction and Outcomes of Deroofing

Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episode, but we explore the role of Oncotype Dx!Studies discussed in the episode:TAILORxRxPonderFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Dr. Kristi Funk reveals the power you hold to transform your health and prevent breast cancer in just two weeks! Learn how a whole food plant-based diet and exercise can drastically change your blood into a cancer-kicking machine. Dive into the eye-opening study on the Pricin Plan and discover how simple lifestyle changes can significantly lower your breast cancer risk. #BreastCancerAwareness #HealthyLiving #PlantBasedDiet

A fantastic episode for urologists, radiation oncologists, and anyone interested in localised prostate cancer. Biochemical recurrence (BCR) is unfortunately all too common after surgery or radiation for prostate cancer, and today we talk with someone who has been working in BCR for more than 20 years. Dr Steve Freedland, Urologist at Cedars-Sinai in Los Angeles, popped into the GU Cast studio to talk about the landmark series from Johns-Hopkins Medical Institute (links below) which still today remains our best guide to the natural history of BCR after radical prostatectomy. And the key message that PSA doubling time is our most important tool to risk stratify patients reminds true today. And Steve of course is the lead investigator of the EMBARK trial, published in NEJM in 2023, which has led to a new standard of care for men experiencing high-risk BCR after surgery or radiotherapy. EMBARK has clearly shown us that the use of enzaluamide, either on its own, or with androgen deprivation therapy, reduces the risk of metastases when compared with ADT alone. We dive deep into EMBARK with Steve.This is a Themed Podcast supported by our Gold Partners, Astellas. Astellas also supported Steve to be in Australia this week for the USANZ ASM in Perth, and visits to Melbourne and Sydney. Your hosts are Professor Declan Murphy and Dr Renu Eapen. Even better on our Youtube channelLinks:Freedland et al JAMA 2005 EMBARK paper in NEJM

Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway!Studies discussed in the episode:KEYNOTE 355ASCENTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

How does lymph node assessment play a pivotal role in personalized, multidisciplinary care? Credit available for this activity expires: 2/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002279?ecd=bdc_podcast_libsyn_mscpedu

Prevention of breast cancer recurrence is the holy grail, but how much do you know about eating in a way that makes that a reality? It's possible you've been fed inaccurate facts and myths, so Cathy clarifies what eating for prevention looks like and shares two suggestions for a sane, lifelong approach to eating to manage risk. ___________________________ Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here! Follow me on Instagram @hormone.breastcancer.dietitian

March 2025 Journal Club Podcast Title: Gene Expression Changes Associated With Recurrence After Gross Total Resection of Newly Diagnosed World Health Organization Grade 1 Meningioma To read journal article: https://journals.lww.com/neurosurgery/fulltext/2025/03000/gene_expression_changes_associated_with_recurrence.6.aspx Author: Ramin Morshed Guest Faculty: Tomas Garzon-Muvdi Moderator: Kimberly Hoang Resident Planner: Alexander Himstead

Quick apology...My mic wasn't turned on, but at least Samantha sounds great! In this conversation, Jen and Samantha Harris discuss the journey of breast cancer, reflecting on Samantha's initial diagnosis, the challenges of treatment, and the emotional aftermath. They emphasize the importance of self-advocacy, understanding one's body, and the role of lifestyle changes in managing health. The conversation also touches on the recurrence of cancer and the empowerment that comes from knowledge and support systems. Takeaways Samantha reflects on the changes in her life since her last interview. The importance of being proactive in health advocacy is highlighted. The significance of knowing one's body and recognizing changes is emphasized. Samantha discusses the recurrence of her cancer and the fear associated with it. The conversation stresses the need for a supportive medical team. Lifestyle changes play a crucial role in health management post-diagnosis. Samantha shares her approach to navigating treatment options. You can connect with Samantha here: https://samantha-harris.com Samantha Harris Instagram: https://www.instagram.com/samanthaharristv/ RESOURCES & LINKS Midi Health: Take control of your hormonal health with personalized testing and plans. Check out the survivrship program here Non-Toxic Product Recommendations: https://www.jendelvaux.com/Non-toxic-Recommendations CACAO Adaptogen with 4 functional mushrooms. Use HELLO10 for $10 off The BLUEPRINT from Results to Rising details HERE FREE Download of cancer fighting vegan recipes: HERE Connect with me on Instagram: https://www.instagram.com/jendelvaux/ EMAIL ME: coachjennyd@gmail.com FAVORITE TEA: Pique Tea:  https://www.piquetea.com/?rfsn=5818415.d1d969a&utm_source=affiliate

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Amber Orman, MD, DipABLM is a double board-certified radiation oncologist and lifestyle medicine specialist focusing on breast cancer treatment and prevention, providing holistic care that encompasses mind and body. She joined AdventHealth from Moffitt Cancer Center and the University of South Florida Morsani School of Medicine in Tampa, where she served as staff and medical faculty, respectively. She is the first ever Chief Wellness Office (CWO) of AdventHealth Medical Group, working to improve the well-being of her colleagues. She is also the co-founder of the HEAL (Healthy Eating and Active Lifestyle) program at AdventHealth in Orlando, Florida. HEAL is an 8-week lifestyle medicine program designed to educate and inspire cancer patients to make positive changes to decrease cancer recurrence and improve overall healthspan. She collaborates with the American College of Lifestyle Medicine as a member of the Health Systems Council and was a past Chair of the Cancer Member Interest Group. She is the Medical Director of AdventHealth Lifestyle Ventures as well as an Assistant Professor at the University of Central Florida College of Medicine. Her research interests include integrative therapies and their applications to cancer prevention, treatment and survivorship, with a strong emphasis on nutrition.

Send us a textDiscover the hidden complexities behind perineal hernia recurrence in dogs as we chat with Dr. Mandy Wallace and Abigail Hatch. Mandy and Abigail provide fascinating insights into the risks associated with hernia development and the challenges of fecal incontinence. Mandy and Abigail emphasize the crucial need for pet owner education. Their discussion offers a deep dive into the nuances of soft tissue surgery, contrasting it with the generally healthier cases found in orthopedic surgery, while sharing personal journeys that led them to this specialized field.Our conversation also touches on the evolution of veterinary record-keeping, highlighting the shift from paper to electronic systems and how this impacts data collection for retrospective studies. Mandy and Abigail offer their perspectives on improving these practices, guided by their own experiences with scientific writing and mentorship. This episode promises a blend of serious insights and light-hearted moments with two passionate professionals in the veterinary world.JAVMA article: https://doi.org/10.2460/javma.24.07.0487INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Louie Helmecki shares his deeply personal journey through multiple cancer diagnoses, shedding light on the emotional, physical, and medical challenges he faced along the way. From enduring chemotherapy and surgeries to navigating the complexities of cancer recurrence, Louie speaks candidly about the toll of treatment and the resilience required to push forward. He and Freddie Kimmel discuss the critical role of health ownership, the importance of advocating for the right medical care, and the gaps in traditional medicine that often leave patients searching for more holistic solutions. Louie's story is not just about surviving but about reclaiming control over his well-being and redefining what it means to thrive beyond cancer. This conversation also delves into groundbreaking health innovations, including the use of peptides, GLP-1 medications, and lifestyle medicine as tools for recovery and disease prevention. Freddie and Louie explore the latest advancements in cancer detection, weight management, and muscle preservation, emphasizing the importance of a personalized and proactive approach to health. They highlight the growing integration of complementary therapies like red light therapy, IV treatments, and biohacking strategies that support the body's natural healing process. More than just a story of struggle, this episode is a testament to the power of mindset, education, and taking action to build a life beyond illness.Chapters00:00 Introduction to Cancer Journeys05:00 Louie's Cancer Diagnosis and Initial Treatment09:52 Chemotherapy Experiences and Challenges16:01 Surgery and Recovery Insights20:01 Recurrence and New Diagnosis30:00 Navigating Medical Decisions and Expert Opinions35:50 Navigating Cancer Treatment Experiences41:07 The Intersection of Traditional and Complementary Medicine49:01 Innovations in Health and Wellness Practices55:46 Understanding Peptides and Their Impact on Health01:05:59 Exploring Weight Loss Medications01:08:02 The Importance of Comprehensive Health Assessments01:09:55 Navigating Weight Loss Programs Responsibly01:12:03 Innovative Approaches to Health and Wellness01:16:52 Cancer Detection and Preventative Measures01:26:51 Life Lessons from Cancer SurvivalUPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD (30% off)Code: BEAUTIFULLYBROKENSaga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Discover the hidden factors behind the rising breast cancer rates as Dr. Kristi Funk dives deep into the impact of lifestyle and diet. Learn how Asian immigrants in the US experienced a 100% increase in breast cancer rates due to Western lifestyle changes and how you can take control to reduce your risk. Join Dr. Funk as she reveals the powerful influence of nutrition on your health. #BreastCancerPrevention #HealthyLiving #NutritionMatters

In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host for today's episode. Let's dive into a fascinating study published in JCO Precision Oncology entitled, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” This study led by Dr. Eric Michael Lander and colleagues examines a critical question: Can circulating tumor DNA help predict recurrence in patients with esophagogastric cancer who have achieved a favorable pathologic response after treatment? Esophagogastric cancer ranks as the seventh leading cause of cancer-related deaths worldwide. Despite aggressive treatment including neoadjuvant therapy followed by surgery, recurrence remains a grim reality for many patients. Interestingly, even those who achieve a pathologic complete response face a recurrence risk of up to 25%. This highlights a need for better tools to identify high-risk patients post-treatment. Circulating tumor DNA, or ctDNA for short, is emerging as a powerful biomarker in oncology. This minimally invasive blood-based test detects fragments of tumor DNA in the bloodstream, potentially signaling molecular residual disease before any radiographic evidence of recurrence appears. In this study, researchers focused on patients with locoregional esophagogastric cancer who had undergone neoadjuvant therapy followed by surgery, achieving either a complete or near complete pathologic response. Blood samples were collected postoperatively within a 16-week molecular residual disease window and during routine surveillance. The aim is to determine whether ctDNA positivity correlates with recurrence-free survival. The study analyzed 309 plasma samples from 42 patients across 11 institutions. Detectable ctDNA within the 16-week postoperative window was associated with a significantly higher recurrence risk. Among those with detectable ctDNA, 67% experienced recurrence compared to only 15% for those with undetectable ctDNA. This corresponds to a hazard ratio of 6.2, an alarming figure that underscores the potential for ctDNA as a prognostic tool. But the story doesn't end there. Postoperative surveillance ctDNA testing more than 16 weeks after surgery also proved to be a powerful prognostic indicator. Every patient with detectable ctDNA during surveillance eventually experienced recurrence, while only 7.4% of those with undetectable ctDNA relapse. These findings suggest that ctDNA testing could provide a critical lead time, enabling earlier interventions and personalized treatment strategies. Now let's talk about the clinical implications. Currently, patients who achieve a pathologic complete response often aren't considered for adjuvant therapies as the absence of visible disease is taken as a sign of remission. However, this study challenges that assumption. By integrating ctDNA testing into routine post-treatment surveillance, clinicians could identify high-risk patients who might benefit from additional therapy even when traditional imaging shows no signs of recurrence. This brings us to the bigger picture. Esophagogastric cancer treatment is evolving rapidly, with trials like CheckMate 577 and ESOPEC offering new insights into perioperative strategies. However, this study highlights a critical gap, the need for personalized, biomarker-driven approaches in the adjuvant setting. ctDNA could fill that gap, offering a non-invasive, dynamic way to monitor patients and guide clinical decisions. Of course, no study is without its limitations. The authors acknowledge the relatively small sample size and the retrospective nature of their analysis. They also note the variability in ctDNA testing and imaging schedules across institutions. However, the robust association between ctDNA positivity and recurrence-free survival makes a compelling case for further research in larger prospective cohorts. Looking ahead, what's the next step? The authors call for prospective validation of ctDNA as a prognostic tool, emphasizing its potential to refine risk stratification and optimize treatment strategies. Imagine a future where a simple blood test could dictate not only the need for additional therapies, but also the timing and type of intervention. As we wrap up, let's reflect on the broader impact of the study. By integrating ctDNA into routine cancer care, we could move closer to a world where treatments are not just effective, but also precisely tailored to each patient's unique biology and disease dynamics. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

So many women finish treatment for hormone-driven breast cancer and struggle to navigate their alcohol consumption; it causes so much angst! In today's episode I highlight the connection between alcohol and recurrence risk and guide you through an exercise in decision-making about your own approach to alcohol. If you feel guilty about your nightly wine or weekend martini habit, this is the episode for you!  Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here! Follow me on Instagram @hormone.breastcancer.dietitian

Episode Highlights: Happy New Year from Molly and Clarissa!

Have you checked out the AUA/ASTRO/SUO's recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS The doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options. This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions. --- TIMESTAMPS 00:00 - Introduction 03:41 - Consensus Biochemical Recurrence Guidelines 08:56 - Evolution of Post-Prostatectomy Biochemical Recurrence Management 13:24 - Patient Counseling and Risk of Recurrence 17:42 - PSMA PET Scans 20:44 - Postoperative PSA Monitoring 28:35 - The Role of Radiation 31:56 - Hormone Therapy 39:00 - Salvage Lymphadenectomy 46:30 - Future Directions and Concluding Thoughts --- RESOURCES Veracyte https://www.veracyte.com/ Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024) https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer

Stay up to date in your bladder cancer practice with this insightful episode of the BackTable Urology podcast, developed in collaboration with the Society of Urologic Oncology. Dr. Betsy Koehne (University of Wisconsin) and Dr. Amir Salmasi (UC San Diego) talk through the contemporary management of low and intermediate-risk non-muscle-invasive bladder cancer. --- SYNPOSIS The doctors explore the challenges and nuances of patient communication, intravesical therapy, and postoperative surveillance. They also cover emerging treatments and clinical trials that hold promise for improving patient outcomes and quality of life. Emphasis is placed on the distress experienced by patients and the need for personalized treatments. --- TIMESTAMPS 00:00 - Introduction 01:51 - Initial Consultation 08:01 - TURBT Procedure Insights 23:14 - Managing Low and Intermediate Risk Bladder Cancer 26:47 - Recurrence and Surveillance Strategies 27:48 - Prognostication Tools 30:10 - Intravesical Chemotherapy Options 33:24 - High Grade Tumors 42:33 - Clinical Trials and Emerging Therapies 49:19 - Concluding Thoughts

TODAY ON THE ROBERT SCOTT BELL SHOW: Unhealthy Diet Diseases, Dr. Robert Bard, Cancer recurrence prevention, Aloe Socotrina, CDC Hyper-Vaccination Agenda, Hava Levi & Nicole Dromy, Herbal Healing, Vitamin D3 Rat Poison, Babies' Werewolf Syndrome and MORE! https://robertscottbell.com/unhealthy-diet-diseases-dr-robert-bard-cancer-recurrence-prevention-aloe-socotrina-cdc-hyper-vaccination-agenda-hava-levi-nicole-dromy-herbal-healing-vitamin-d3-rat-poison-babies-w/

Biochemical recurrence of prostate cancer can be difficult to diagnose and treat. In this episode of BackTable Urology, where Dr. Aditya Bagrodia hosts Dr. Amar Kishan, a genitourinary radiation oncologist at UCLA, to discuss the complexities of biochemical recurrence and local failure after radiation therapy for prostate cancer. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS First, they evaluate alternatives to androgen deprivation therapy (ADT), the benefits and risks associated with ADT, and the role of genetic classifier tests. They also detail the goals of prostate-specific antigen (PSA) monitoring, PSA trends post-radiation, and advancements in PSMA PET scans. Then, the conversation highlights modern treatment options like targeted radiation, low dose rate brachytherapy, salvage radical prostatectomy, and focal therapy. Finally, the doctors emphasize personalized and multidisciplinary treatment plans as they hope to improve long-term outcomes for patients with prostate cancer. --- TIMESTAMPS 00:00 - Introduction 04:31 - PSA Levels Post-Radiation 13:21 - Local Recurrence and PSMA PET 21:29 - Explaining Radiation Effects to Patients 22:41 - Managing PSA Bounce 26:05 - Imaging and Biopsy Techniques 28:55 - Treatment Options for Local Recurrence 30:16 - Re-Irradiation and Focal Therapy 33:13 - Concluding Thoughts --- RESOURCES Veracyte https://www.veracyte.com/

On today's episode, we are discussing a topic that affects most women with hormone receptor-positive, early-stage breast cancer after they finish their initial treatment and begin navigating survivorship. To lower the risk of recurrence, most women begin taking anti-estrogen therapy, also called hormone therapy or endocrine therapy, but these treatments do not come without the risk of side effects. When side effects become severe, survivors may be faced with the task of weighing the benefits of hormone therapy against the associated side effects. This can be challenging and may even lead them to wonder how much longer they need to continue on the medication. Joining us today to discuss how patients and providers can balance fear of recurrence against potential side effects of treatment and how genomic testing can help guide treatment decisions is a Nurse Practitioner at Memorial Sloan-Kettering Cancer Center, Adriana Olivo. This podcast is sponsored by Biotheranostics Inc., a Hologic Company. The Breast Cancer Index test is the only test recognized by the NCCN guidelines and the ASCO Clinical Practice Guideline to predict which patients are likely to benefit from extension of adjuvant anti-estrogen therapy beyond 5 years.